Biomarker Signatures Linked to Ethnicity May Predict Prostate Cancer Risk

Share this content:
Disparities in prostate cancer outcomes between African-, European-American patients can partially be explained by genetic/biologic factors.
Disparities in prostate cancer outcomes between African-, European-American patients can partially be explained by genetic/biologic factors.

Ethnic disparities in prostate cancer outcomes between African American and European American patients can partially be explained by genetic/biologic factors, according to a recent article printed in the Journal of Clinical Oncology.

A total of 154 African American and European American patients from four medical centers were matched according to the Cancer of the Prostate Risk Assessment postsurgical score within each institution.

The distribution of mRNA expression levels of 20 validated biomarkers reported to be associated with prostate cancer initiation and progression was compared with ethnicity.

RELATED: Study Suggests 90% of Advanced Prostate Cancers May Have Anomaly that May Influence Treatment

Of the 20 biomarkers examined, six showed statistically significant differential expression between groups: ERG (P<0.001), AMACR (P<0.001), SPINK1 (P=0.001, NKX3-1 (P=0.03), GOLM1 (P=0.03), and androgen receptor (P=0.04).

Dysregulation of GOLM1 (P=0.037), SRD5A2 (P=0.023) predicted clinical outcomes, including 3-year biochemical recurrence and metastasis at 5 years. A greater proportion of African American men than European men had triple-negative (ERG-/ETS-/SPINK1-negative) disease (51% vs. 35%; P=0.002).

Reference

  1. Yamoah K, Johnson MH, Choeurng V, et al. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2014.59.8912.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters